Evidence map›Paper›PMID 38256556›Full record

ArticleJournal of clinical medicine2024

Performance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction.

Mladen Marinkovic, Suzana Stojanovic-Rundic, Aleksandra Stanojevic, Aleksandar Tomasevic, Radmila Jankovic, Jerome Zoidakis, Sergi Castellví-Bel, Remond J A Fijneman, Milena Cavic, Marko Radulovic

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A novel approach to radioembolization treatment planning using a hybrid [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mladen MarinkovicClinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-8437-3493
Suzana Stojanovic-RundicClinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-8680-4920
Aleksandra StanojevicDepartment of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-9179-2856
Aleksandar TomasevicClinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-2715-3504
Radmila JankovicDepartment of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0003-2990-0523
Jerome ZoidakisDepartment of Biotechnology, Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece.ORCID 0000-0002-4557-3430
Sergi Castellví-BelGastroenterology Deparment, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Clínic Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-1217-5097
Remond J A FijnemanDepartment of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-2076-5521
Milena CavicDepartment of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-7604-9295
Marko RadulovicDepartment of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-2314-7457

Funding

Horizon Europe Twinning Project STEPUPIORS 101079217Ministry of Science, Technology Development and Innovation of the Republic of Serbia 451-03-47/2023-01/200043
6 · The paper itself

Abstract

(1) Background: This study aimed to develop a machine learning model based on radiomics of pretreatment magnetic resonance imaging (MRI) 3D T2W contrast sequence scans combined with clinical parameters (CP) to predict neoadjuvant chemoradiotherapy (nCRT) response in patients with locally advanced rectal carcinoma (LARC). The study also assessed the impact of radiomics dimensionality on predictive performance. (2) Methods: Seventy-five patients were prospectively enrolled with clinicopathologically confirmed LARC and nCRT before surgery. Tumor properties were assessed by calculating 2141 radiomics features. Least absolute shrinkage selection operator (LASSO) and multivariate regression were used for feature selection. (3) Results: Two predictive models were constructed, one starting from 72 CP and 107 radiomics features, and the other from 72 CP and 1862 radiomics features. The models revealed moderately advantageous impact of increased dimensionality, with their predictive respective AUCs of 0.86 and 0.90 in the entire cohort and 0.84 within validation folds. Both models outperformed the CP-only model (AUC = 0.80) which served as the benchmark for predictive performance without radiomics. (4) Conclusions: Predictive models developed in this study combining pretreatment MRI radiomics and clinicopathological features may potentially provide a routine clinical predictor of chemoradiotherapy responders, enabling clinicians to personalize treatment strategies for rectal carcinoma.

Indexed as

chemoradiotherapyMRIneoadjuvantradiomicsrectal carcinoma

Identifiers

PMID38256556
PMCPMC10816962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.